Cytosorbents (CTSO) Operating Expenses (2010 - 2026)

Cytosorbents (CTSO) has reported Operating Expenses for 17 consecutive years, with $9.7 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Operating Expenses fell 7.11% year-over-year to $9.7 million; the trailing twelve-month figure through Jun 2026 stood at $39.6 million (down 1.69% YoY), and the FY2025 full-year result was $41.2 million, changed 0.24% from the prior year.
• Operating Expenses rose to $9.7 million in Q2 2026 per CTSO's latest filing, from $9.2 million in the prior quarter.
• Across five years, Operating Expenses topped out at $14.6 million in Q4 2023 and bottomed at $9.2 million in Q1 2026.
• Historically, Operating Expenses has averaged $11.5 million across 5 years, with a median of $11.4 million in 2024.
• The sharpest annual moves came in 2022 and 2024: Operating Expenses surged 32.76% in 2022, then sank 34.1% in 2024.
• Over 5 years, Operating Expenses stood at $12.1 million in 2022, then gained by 20.88% to $14.6 million in 2023, then tumbled by 34.1% to $9.6 million in 2024, then climbed by 15.95% to $11.2 million in 2025, then fell by 13.42% to $9.7 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $9.7 million, $9.2 million, and $11.2 million for Q2 2026, Q1 2026, and Q4 2025 respectively.